Anika Therapeutics (ANIK) Competitors $11.50 +0.19 (+1.68%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$11.52 +0.02 (+0.13%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANIK vs. ANVS, CERS, OSUR, UTMD, WST, COO, ALGN, MMSI, HAE, and ICUIShould you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include Annovis Bio (ANVS), Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), West Pharmaceutical Services (WST), Cooper Companies (COO), Align Technology (ALGN), Merit Medical Systems (MMSI), Haemonetics (HAE), and ICU Medical (ICUI). These companies are all part of the "medical" sector. Anika Therapeutics vs. Its Competitors Annovis Bio Cerus OraSure Technologies Utah Medical Products West Pharmaceutical Services Cooper Companies Align Technology Merit Medical Systems Haemonetics ICU Medical Anika Therapeutics (NASDAQ:ANIK) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation. Do insiders & institutionals believe in ANIK or ANVS? 91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 9.6% of Anika Therapeutics shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend ANIK or ANVS? Anika Therapeutics presently has a consensus target price of $20.00, indicating a potential upside of 73.91%. Annovis Bio has a consensus target price of $18.00, indicating a potential upside of 517.50%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than Anika Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor ANIK or ANVS? In the previous week, Anika Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Anika Therapeutics and 1 mentions for Annovis Bio. Anika Therapeutics' average media sentiment score of 0.93 beat Annovis Bio's score of 0.92 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ANIK or ANVS? Anika Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Is ANIK or ANVS more profitable? Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -41.28%. Anika Therapeutics' return on equity of -7.22% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Anika Therapeutics-41.28% -7.22% -5.64% Annovis Bio N/A -300.56%-193.50% Which has preferable earnings and valuation, ANIK or ANVS? Annovis Bio has lower revenue, but higher earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnika Therapeutics$119.91M1.38-$56.38M-$3.88-2.96Annovis BioN/AN/A-$24.59M-$2.16-1.35 SummaryAnnovis Bio beats Anika Therapeutics on 8 of the 15 factors compared between the two stocks. Get Anika Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIK vs. The Competition Export to ExcelMetricAnika TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.20M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E Ratio-2.9621.1828.1020.05Price / Sales1.38286.99429.3789.38Price / Cash118.5742.7636.2258.56Price / Book1.098.378.665.87Net Income-$56.38M-$55.19M$3.25B$258.55M7 Day Performance9.52%5.88%4.22%3.73%1 Month Performance6.19%17.33%10.51%11.75%1 Year Performance-58.78%4.42%34.40%18.03% Anika Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIKAnika Therapeutics4.1409 of 5 stars$11.50+1.7%$20.00+73.9%-59.4%$162.20M$119.91M-2.96300Positive NewsANVSAnnovis Bio1.8523 of 5 stars$2.87+5.7%$18.00+528.3%-72.1%$55.84MN/A-1.333CERSCerus2.8639 of 5 stars$1.45flat$3.50+141.4%-41.6%$277.18M$185.14M-14.50290Positive NewsUpcoming EarningsOSUROraSure Technologies2.4364 of 5 stars$3.07-1.0%$3.00-2.3%-23.3%$229.64M$185.83M-7.31840Positive NewsHigh Trading VolumeUTMDUtah Medical Products1.8854 of 5 stars$56.69+0.5%N/A-16.9%$184.24M$40.90M15.00180News CoverageEarnings ReportWSTWest Pharmaceutical Services4.4658 of 5 stars$224.66-1.1%$320.00+42.4%-5.0%$16.14B$2.89B35.2710,600Trending NewsEarnings ReportDividend IncreaseAnalyst ForecastCOOCooper Companies3.2947 of 5 stars$73.61-1.6%$99.70+35.4%-19.5%$14.72B$3.90B35.7316,000Analyst UpgradeALGNAlign Technology4.6628 of 5 stars$199.31-1.5%$242.92+21.9%-9.1%$14.45B$4.00B36.3020,945Positive NewsUpcoming EarningsMMSIMerit Medical Systems4.236 of 5 stars$93.450.0%$109.11+16.8%-0.4%$5.52B$1.36B45.817,400Positive NewsUpcoming EarningsHAEHaemonetics4.9292 of 5 stars$76.59+1.4%$97.30+27.0%-17.0%$3.68B$1.36B23.143,023ICUIICU Medical4.3627 of 5 stars$130.85-1.0%$192.67+47.2%+4.4%$3.22B$2.42B-34.1615,000News CoveragePositive News Related Companies and Tools Related Companies Annovis Bio Alternatives Cerus Alternatives OraSure Technologies Alternatives Utah Medical Products Alternatives West Pharmaceutical Services Alternatives Cooper Companies Alternatives Align Technology Alternatives Merit Medical Systems Alternatives Haemonetics Alternatives ICU Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIK) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhat I told my neighbor to do with his moneyWhen a close friend inherited money, Joel Litman gave him the same investment advice he gives his own mom. ...Altimetry | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.